<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472822</url>
  </required_header>
  <id_info>
    <org_study_id>BIOYD-KA-SCHISANDRA</org_study_id>
    <nct_id>NCT01472822</nct_id>
  </id_info>
  <brief_title>Efficacy of Omija (Schisandra Chinensis) Extract in Subjects With Knee Osteoarthritis</brief_title>
  <official_title>Efficacy and Safety of Omija Extract on Gonarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee osteoarthritis (KO) is a common arthropathy and a leading cause of disability in elderly
      adults. Schizandra chinensis(Omija) has been known to have five predominant tastes: salty,
      sweet, sour, astringent, and bitter. It has also been shown to have various effects on the
      anti-inflammatory, cardiovascular system, gastrointestinal system, central nervous system,
      endocrine system, and stress protect. Therefore, this study is designed to evaluate the
      efficacy and safety on KO of Omija extract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study, the investigators will assess the efficacy and safety of the
      formulation of Omija extract(1,200 mg administered twice a day) on the symptoms of knee
      osteoarthritis (KO) during a 12-week treatment course. In a randomized, double-blind
      placebo-controlled trial, subjects will be randomly assign to receive oral omija treatment
      group(n=30) or placebo group(n=30). The primary efficacy outcome measure will be score change
      in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) after 12-weeks.
      Secondary parameters will be included the Lysholm index score, hs-CRP, osteocalcin(OSC), and
      deoxypyridinoline(DPYR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0-96) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Lysholm Index Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Lysholm index score total score (score 0-100) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down&amp;up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</measure>
    <time_frame>12 weeks</time_frame>
    <description>hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OSC(Osteocalcin)</measure>
    <time_frame>12 weeks</time_frame>
    <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in DPD(Deoxypyridinoline)</measure>
    <time_frame>12 weeks</time_frame>
    <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Mild Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Omija extract.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omija extract.</intervention_name>
    <description>Omija extract 1.2g/day for 12weeks</description>
    <arm_group_label>Omija extract.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1.2g/day for 12weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 30-70 years old

          -  mild to Moderate KO(Knee Osteoarthritis) as indicated by WOMAC(Western Ontario and
             McMaster University Osteoarthritis Index) score â‰¥ 38

          -  Able to walk

          -  Subject agrees not to start any new therapies for OA during the course of the study

          -  Able to give informed consent

        Exclusion Criteria:

          -  History of underlying inflammatory arthropathy; septic arthritis; inflammatory joint
             disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia;
             Wilson's disease; ochronosis; haemochromatosis; heritable arthritic disorder or
             collagen gene mutations or rheumatoid arthritis

          -  Expectation of surgery in the next 4 months

          -  Recent injury in the area affected by OA of the knee, i.e. meniscal tear (past 4
             months)

          -  Cartilage reconstruction procedure in the target knee

          -  Intra-articular corticosteroid injections in the target knee within the last 3 months

          -  Viscous injections in the target knee within the last 6 months

          -  Abnormal liver or kidney function tests (ALT or AST &gt; 2 times the upper limit of
             normal; elevated creatinine, males&gt;125 umol/L, females&gt;110 umol/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Hwan Seo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>560-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>December 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2013</results_first_posted>
  <last_update_submitted>December 27, 2012</last_update_submitted>
  <last_update_submitted_qc>December 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>Omija</keyword>
  <keyword>knee osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through local advertising and doctor referrals from hospital outpatients and general practice clinics.</recruitment_details>
      <pre_assignment_details>The criteria were an age from 30 to 70 years, mild to Moderate KO as indicated by WOMAC(Western Ontario and McMaster Universities Arthritis Index) score â‰¥ 38 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Omija Extract.</title>
          <description>Omija extract.(2times/day, 4tablets/day, 1.2g/day) for 12weeks
Omija extract.: Omija extracted with ethanol and then concentrated and dried.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo(2times/day, 4tablets/day, 1.2g/day) for 12weeks
Placebo : Amount and calorie of placebo are same with Omija extract..</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omija</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="9.5"/>
                    <measurement group_id="B2" value="52.4" spread="9.6"/>
                    <measurement group_id="B3" value="52.2" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score</title>
        <description>WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0â€“96) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score</title>
          <description>WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0â€“96) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).</description>
          <population>per protocol analysis</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1(0 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" spread="11.6"/>
                    <measurement group_id="O2" value="53.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3(12 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="17.2"/>
                    <measurement group_id="O2" value="31.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lysholm Index Score</title>
        <description>Lysholm index score total score (score 0â€“100) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down&amp;up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lysholm Index Score</title>
          <description>Lysholm index score total score (score 0â€“100) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down&amp;up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).</description>
          <population>per protocol analysis</population>
          <units>units on a scale(0-100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1(0 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="11.0"/>
                    <measurement group_id="O2" value="48.3" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3(12 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" spread="10.8"/>
                    <measurement group_id="O2" value="59.9" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</title>
        <description>hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</title>
          <description>hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1(0 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3(12 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                    <measurement group_id="O2" value="0.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in OSC(Osteocalcin)</title>
        <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in OSC(Osteocalcin)</title>
          <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1(0 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="6.2"/>
                    <measurement group_id="O2" value="16.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3(12 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="5.3"/>
                    <measurement group_id="O2" value="17.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in DPD(Deoxypyridinoline)</title>
        <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in DPD(Deoxypyridinoline)</title>
          <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>nanoMolar DPD per milliMolar creatine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1(0 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.5"/>
                    <measurement group_id="O2" value="7.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3(12 week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.9"/>
                    <measurement group_id="O2" value="7.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Omija</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeong-Hwan Seo, MD</name_or_title>
      <organization>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</organization>
      <phone>82-63-276-8284</phone>
      <email>vivaseo@jbnu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

